I 

112TH CONGRESS 

1ST SESSION H. R. 1254 

To amend the Controlled Substances Act to place synthetic drugs in Schedule 

I. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 30, 2011 

Mr. DENT (for himself, Mr. MEEHAN, Mr. MARINO, Mr. PLATTS, Mr. 

BARLETTA, Mr. CUELLAR, Mrs. EMERSON, Mrs. BIGGERT, Mr. 

LATOURETTE, Mr. GIBSON, Mr. STIVERS, and Mr. REED) introduced the 

following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period 

to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee 

concerned 

A BILL 

To amend the Controlled Substances Act to place synthetic 

drugs in Schedule I. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Synthetic Drug Con5 trol Act of 2011’’. 


emcdonald on DSK2BSOYB1PROD with BILLS
2 

•HR 1254 IH

1 SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I 

2 OF THE CONTROLLED SUBSTANCES ACT. 

3 (a) CANNABIMIMETIC AGENTS.—Schedule I, as set 

4 forth in section 202(c) of the Controlled Substances Act 

5 (21 U.S.C. 812(c)) is amended by adding at the end the 

6 following: 

7 ‘‘(d)(1) Unless specifically exempted or unless listed 

8 in another schedule, any material, compound, mixture, or 

9 preparation which contains any quantity of 

10 cannabimimetic agents, or which contains their salts, iso11 mers, and salts of isomers whenever the existence of such 

12 salts, isomers, and salts of isomers is possible within the 

13 specific chemical designation. 

14 ‘‘(2) In paragraph (1), the term ‘cannabimimetic 

15 agents’— 

16 ‘‘(A) means any substance that is a cannabinoid 

17 receptor type 1 (CB1 receptor) agonist as dem18 onstrated by binding studies and functional assays 

19 within the following structural classes: 

20 ‘‘(i) 2-(3-hydroxycyclohexyl)phenol with 

21 substitution at the 5-position of the phenolic 

22 ring by alkyl or alkenyl, whether or not sub23 stituted on the cyclohexyl ring to any extent. 

24 ‘‘(ii) 3-(1-naphthoyl)indole or 3-(1- 

25 naphthyl)indole by substitution at the nitrogen 

26 atom of the indole ring, whether or not further 


emcdonald on DSK2BSOYB1PROD with BILLS
3 

•HR 1254 IH

1 substituted on the indole ring to any extent, 

2 whether or not substituted on the naphthoyl or 

3 naphthyl ring to any extent. 

4 ‘‘(iii) 3-(1-naphthoyl)pyrrole by substi5 tution at the nitrogen atom of the pyrrole ring, 

6 whether or not further substituted in the indole 

7 ring to any extent, whether or not substituted 

8 on the naphthoyl ring to any extent. 

9 ‘‘(iv) 1-(1-naphthylmethyl)indene by substi10 tution of the 3-position of the indene ring, 

11 whether or not further substituted in the indene 

12 ring to any extent, whether or not substituted 

13 on the naphthyl ring to any extent. 

14 ‘‘(v) 3-phenylacetylindole or 3- 

15 benzoylindole by substitution at the nitrogen 

16 atom of the indole ring, whether or not further 

17 substituted in the indole ring to any extent, 

18 whether or not substituted on the phenyl ring 

19 to any extent.; and 

20 ‘‘(B) includes— 

21 ‘‘(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- 

22 hydroxycyclohexyl]-phenol (CP-47,497); 

23 ‘‘(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- 

24 hydroxycyclohexyl]-phenol (cannabicyclohexanol 

25 or CP-47,497 C8-homolog); 


emcdonald on DSK2BSOYB1PROD with BILLS
4 

•HR 1254 IH

1 ‘‘(iii) 1-pentyl-3-(1-naphthoyl)indole 

2 (JWH-018 and AM678); 

3 ‘‘(iv) 1-butyl-3-(1-naphthoyl)indole (JWH4 073); 

5 ‘‘(v) 1-hexyl-3-(1-naphthoyl)indole (JWH6 019); 

7 ‘‘(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph8 thoyl)indole (JWH-200); 

9 ‘‘(vii) 1-pentyl-3-(2- 

10 methoxyphenylacetyl)indole (JWH-250); 

11 ‘‘(viii) 1-pentyl-3-[1-(4- 

12 methoxynaphthoyl)]indole (JWH-081); 

13 ‘‘(ix) 1-pentyl-3-(4-methyl-1-naph14 thoyl)indole (JWH-122); 

15 ‘‘(x) 1-pentyl-3-(4-chloro-1-naph16 thoyl)indole (JWH-398); 

17 ‘‘(xi) 1-(5-fluoropentyl)-3-(1-naph18 thoyl)indole (AM2201); 

19 ‘‘(xii) 1-(5-fluoropentyl)-3-(2- 

20 iodobenzoyl)indole (AM694); 

21 ‘‘(xiii) 1-pentyl-3-[(4-methoxy)-ben22 zoyl]indole (SR-19 and RCS-4); 

23 ‘‘(xiv) 1-cyclohexylethyl-3-(2- 

24 methoxyphenylacetyl)indole (SR-18 and RCS25 8); and 


emcdonald on DSK2BSOYB1PROD with BILLS
5 

•HR 1254 IH

1 ‘‘(xv) 1-pentyl-3-(2- 

2 chlorophenylacetyl)indole (JWH-203).’’. 

3 (b) OTHER DRUGS.—Schedule I of section 202(c) of 

4 the Controlled Substances Act (21 U.S.C. 812(c)) is 

5 amended in subsection (c) by adding at the end the fol6 lowing: 

7 ‘‘(18) 4-methylmethcathinone (Mephedrone). 

8 ‘‘(19) 3,4-methylenedioxypyrovalerone (MDPV). 

9 ‘‘(20) 3,4-methylenedioxymethcathinone 

10 (methylone). 

11 ‘‘(21) Naphthylpyrovalerone (naphyrone). 

12 ‘‘(22) 4-fluoromethcathinone (flephedrone). 

13 ‘‘(23) 4-methoxymethcathinone (methedrone; 

14 Bk-PMMA). 

15 ‘‘(24) Ethcathinone. 

16 ‘‘(25) 3,4-methylenedioxyethcathinone 

17 (ethylone). 

18 ‘‘(26) Beta-keto-N-methyl-3,4- 

19 benzodioxyolybutanamine (butylone). 

20 ‘‘(27) N,N-dimethylcathinone 

21 (metamfepramone). 

22 ‘‘(28) Alpha-pyrrolidinopropiophenone (alpha23 PPP). 

24 ‘‘(29) 4-methoxy-alpha25 pyrrolidinopropiophenone (MOPPP). 


emcdonald on DSK2BSOYB1PROD with BILLS
6 

•HR 1254 IH

1 ‘‘(30) 3,4-methylenedioxy-alpha2 pyrrolidinopropiophenone (MDPPP). 

3 ‘‘(31) Alpha-pyrrolidinovalerophenone (alpha4 PVP). 

5 ‘‘(32) 6,7-dihydro-5H-indeno(5,6-d)-1,3-dioxal6 6-amine) (MDAI).’’. 

7 SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 

8 HAZARDS TO PUBLIC SAFETY EXPANSION. 

9 Section 201(h)(2) of the Controlled Substances Act 

10 (21 U.S.C. 811(h)(2)) is amended— 

11 (1) by striking ‘‘one year’’ and inserting ‘‘2 

12 years’’; and 

13 (2) by striking ‘‘six months’’ and inserting ‘‘1 

14 year’’. 

Æ 


emcdonald on DSK2BSOYB1PROD with BILLS